Clinical trials: Insulin-Like Growth Factor I Deficiency
- Condition Insulin-Like Growth Factor I Deficiency
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Growth Disorders
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
This is an extension study to Tercica study MS301 (NCT00125164) and is intended to collect long term safety and efficacy data on the continued use of recombinant human insulin-like growth factor-1 (rh IGF-1) in children and…
- Trial name
- NCT00330668
- Testing
- rh IGF-1 (mecasermin)
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Ipsen
IGF-1 Deficiency
IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population
To determine the normative ranges of the Insulin-like Growth Factor 1 (IGF-1), Insulin-like growth factor-binding protein 3 (IGFBP-3), Acid-Labile Subunit (ALS) according to age, sex and pubertal stage of a healthy paediatric…
- Trial name
- EDISON (NCT01676090)
- Where
- 9 sites in Spain
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Ipsen
Insulin-like Growth Factor-1 Deficiency
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
IGF-1 (insulin-like growth factor-1) is a hormone that is normally produced in the body in response to another hormone called growth hormone. Growth Hormone is produced by a small gland at the base of the brain (the pituitary).
- Trial name
- NCT00572156
- Testing
- NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Ipsen
Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
This study is intended to assess the effects of once daily dosing of recombinant human insulin-like growth factor (rhIGF-1) in increasing height velocity.
- Trial name
- NCT00125190
- Testing
- rhIGF-1 (mecasermin) for a period of 86 weeks
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Primary Insulin-like Growth Factor-1 Deficiency
IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex
This project is a retrospective (beginning January 2006) and prospective patient registry program sponsored by Ipsen (formerly Tercica, Inc.).
- Trial name
- NCT00747604
- Testing
- mecasermin [rDNA origin] injection
- Where
- United States
- Volunteers
- 1,378 people
- Sponsor
- Ipsen
Growth Hormone Deficiency
IGF1 Generation Test
To assess the predictive value of the short term IGF-1 stimulation test, based on IGF-1 changes, on the 24 months growth response to 2 different doses of GH in patients with conventional GH deficiency.
- Trial name
- CAREL (NCT00145457)
- Testing
- Blood sample, Radiography
- Where
- 8 sites in France
- Volunteers
- 82 people
- Sponsor
- Pfizer
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of prepubertal children with short stature…
- Trial name
- NCT00125164
- Testing
- rhIGF-1 (mecasermin, Tercica, Inc.)
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Ipsen
IGF1 Deficiency
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
The Increlex® Global Registry is a descriptive, multicenter, observational, prospective, open-ended, non interventional, post-authorisation surveillance registry.
- Trial name
- NCT00903110
- Testing
- Increlex®
- Where
- 58 sites in United States, Austria and 9 more
- Volunteers
- 500 people
- Sponsor
- Esteve Pharmaceuticals, S.A.